Anebulo Pharmaceuticals (NASDAQ:ANEB) Shares Down 7.8% – Here’s What Happened

Posted by Stanley Muller on Aug 9th, 2026

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) was down 7.8% during trading on Friday . The company traded as low as $0.3044 and last traded at $0.3044. Approximately 100 shares changed hands during trading, a decline of 100% from the average session volume of 34,430 shares. The stock had previously closed at $0.33.

Anebulo Pharmaceuticals Trading Down 7.8%

The company has a fifty day moving average of $0.36 and a two-hundred day moving average of $0.53. The stock has a market capitalization of $12.41 million, a price-to-earnings ratio of -1.60 and a beta of -1.82.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 28.40% of the company’s stock.

About Anebulo Pharmaceuticals

(Get Free Report)

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.